Lawrence Bloch, M.D., J.D.
Lawrence Bloch, M.D., J.D. is president of Infinity. He joined the company as chief financial officer and chief business officer in 2012 and has played a key role in developing and executing the company’s corporate and financial strategies. Prior to joining Infinity in 2012, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a company focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc., raising $150 million in equity and $20 million in venture debt to support the commercial launch of BiDil®. From 1999 to 2004, he served as chief financial officer and vice president of business development of Applied Molecular Evolution, Inc., leading the company’s $101 million initial public offering and $420 million merger with Eli Lilly and Company.
Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Women’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an MBA from Harvard Business School.
Claudio Dansky Ullmann, M.D.
Senior Vice President, Clinical Development
Claudio Dansky Ullmann, M.D., serves as senior vice president, clinical development at Infinity and has nearly 30 years of experience in drug development. Dr. Dansky Ullmann joined Infinity as vice president, clinical development in 2015 and has since led Infinity’s clinical development team. Prior to joining Infinity, he served as a senior medical director, global clinical lead, at Takeda Pharmaceutical Company Limited from 2012 to 2015. From 2005 to 2012, Dr. Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute as a senior investigator where he participated in numerous early-phase and late-phase clinical trials, including studies evaluating treatments for lung and head and neck cancers, melanoma and other solid tumors. During his career, Dr. Dansky Ullmann also held research roles at the National Institute of Health and at Biomira Inc., and he held postdoctoral fellowship positions in tumor immunology and drug resistance at the National Cancer Institute. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, Universidad de Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.
Jeffery Kutok, M.D., Ph.D.
Chief Scientific Officer
Jeffery Kutok, M.D., Ph.D. serves as Infinity’s chief scientific officer. Prior to joining Infinity in 2010, Dr. Kutok was an associate professor of pathology at Harvard Medical School and Brigham and Women’s Hospital. His laboratory focused on translational medicine research and biomarker identification in cancer, and he is an author on over 190 journal articles, reviews and book chapters. Dr. Kutok is board certified in Anatomic Pathology and Hematology and had clinical duties in Hematopathology and Molecular Diagnostics at Brigham and Women’s Hospital. Dr. Kutok received his B.S. in biology and his M.D., Ph.D. in medicine and molecular pathology from the State University of New York at Stony Brook. His Ph.D. was earned working in the laboratory of Dr. Barry Coller, M.D. in the field of platelet pathobiology. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Gary Gilliland, M.D., Ph.D.
Chair and Chief Executive Officer
Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer.
Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is the vice chairman of the Board of Project Hope. She is a past member of the Boards of Padlock Therapeutics, prior to its acquisition by Bristol-Myers Squibb, and the Massachusetts Life Science Center.
Vice President, General Counsel and Secretary
Seth Tasker is vice president, general counsel and secretary and holds responsibility for all aspects of Infinity’s legal affairs as well the company’s human resources and information technology functions. Mr. Tasker has more than 15 years of experience in the pharmaceutical industry and brings expertise in corporate finance and partnering transactions, corporate governance, securities, compliance, employment law and other legal and operational issues relevant to developing new medicines in both the private and public company setting. Prior to joining Infinity, Mr. Tasker served as associate counsel at Surface Logix, Inc., a privately held biotechnology company that invented a platform technology for developing improved drug therapies, resulting in a pipeline of drug candidates addressing Type 2 diabetes, cardiovascular health and oncology. Mr. Tasker received a J.D. and M.B.A from Suffolk University and a B.S. in microbiology from the University of Vermont.